Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Pulmicort

 
National Institutes of Health

Related topics

Related topics

7 relations
120 ACTUAT Budesonide 0.18 MG/ACTUAT Dry Powder Inhaler [Pulmicort]60 ACTUAT Budesonide 0.09 MG/ACTUAT Dry Powder Inhaler [Pulmicort]Budesonide 0.125 MG/ML Inhalant Solution [Pulmicort]Budesonide 0.25 MG/ML Inhalant Solution [Pulmicort]

Broader (3)

Bronchodilator AgentsBudesonidesteroidal anti-inflammatory drugs

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
A randomised, double-blind, placebo-controlled trial of repeated nebulisation of non-viral cystic fibrosis transmembrane conductance regulator ( CFTR) gene therapy in patients with cystic fibrosis
Background Cystic fibrosis (CF) is a chronic, life-limiting disease caused by mutations in the CF transmembrane conductance… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2016
2016
Lung inflammatory and oxidative alterations after exogenous surfactant therapy fortified with budesonide in rabbit model of meconium aspiration syndrome.
Meconium aspiration syndrome (MAS) triggers inflammatory and oxidative pathways which can inactivate both pulmonary surfactant… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2016
2016
[Impact and Effect of Preoperative Short-term Pulmonary Rehabilitation Training on 
Lung Cancer Patients with Mild to Moderate Chronic Obstructive Pulmonary Disease: 
A Randomized Trial].
BACKGROUND Pulmonary rehabilitation (PR) is proposed as an effective strategy to decrease surgical morbidity. However… Expand
2011
2011
Comparison of Symbicort® versus Pulmicort® on steroid pharmacodynamic markers in asthma patients.
BACKGROUND Combination therapy with inhaled corticosteroids (ICS) and long-acting β(2)-adrenergic agonists (LABA) is reported to… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
2009
2009
Measuring charge and mass distributions in dry powder inhalers using the electrical Next Generation Impactor (eNGI).
The electrical Next Generation Impactor (eNGI) was assessed against the electrical low-pressure impactor (ELPI) and next… Expand
  • figure 1
  • figure 5
  • figure 6
  • figure 7
  • figure 8
2005
2005
In vitro comparison of nebulised budesonide (Pulmicort Respules) and beclomethasone dipropionate (Clenil per Aerosol).
This study compared the in vitro performance of two inhaled corticosteroid products for nebulisation, Pulmicort Respules… Expand
Highly Cited
2004
Highly Cited
2004
Effect of a facemask leak on aerosol delivery from a pMDI-spacer system.
The objective of this investigation was to study the relation between size and position of a mask leak on spacer output and lung… Expand
2003
2003
The formulation and evaluation of a CFC-free budesonide pressurised metered dose inhaler.
Although dry powder inhalers are well established for the delivery of corticosteroids, the pressurised metered dose inhaler… Expand
  • figure 2
  • figure 1
  • figure 3
  • figure 4
  • figure 5
2003
2003
Assessment of adrenal suppression from two new dry powder inhaler formulations of budesonide delivered by Clickhaler compared with the Pulmicort Turbuhaler.
Assessment of adrenal suppression via systemic cortisol levels provides an indirect measure of the lung delivery of inhaled… Expand
Highly Cited
1998
Highly Cited
1998
The effects of static charge in spacer devices on glucocorticosteroid aerosol deposition in asthmatic patients.
Electrostatic charge in plastic spacer devices has been shown in vitro to reduce delivery of asthma medications intended for… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE